NVS-ZP7-4

NVS-ZP7-4 is a potent, selective, small-molecule inhibitor of the zinc transporter SLC39A7 (also known as ZIP7), originally developed by Novartis. It serves as a first-in-class chemical tool to investigate the role of endoplasmic reticulum (ER) zinc homeostasis and ZIP7 as a druggable node in the Notch signaling pathway. By inhibiting ZIP7, NVS-ZP7-4 prevents zinc release from the ER into the cytosol, leading to increased ER zinc levels, induction of ER stress, and selective apoptosis in cancer cells, particularly T-cell acute lymphoblastic leukemia (T-ALL) and hepatocellular carcinoma (HCC). Additionally, NVS-ZP7-4 has been shown to modulate ferroptosis, demonstrating protective effects against ferroptotic cell death in certain cancer models. It is currently utilized strictly as a research-use-only compound.

Other names

(S)-1-(2-((6-fluorobenzo[d]thiazol-2-yl)amino)-3-phenylpropyl)-1'H-spiro[piperidine-4,4'-quinazolin]-2'(3'H)-one(S)-1-(2-((6-fluorobenzo[d]thiazol-2-yl)amino)-3-phenylpropyl)-1′H-spiro[piperidine-4,4′-quinazolin]-2′(3′H)-oneNVS-ZP7 4NVS-ZP-7 4NVS-ZP 7 4NVS-ZP74NVS-ZP-74NVS-ZP 74NVSZP7 4NVSZP-7 4NVSZP 7 4NVSZP7-4NVSZP-7-4NVSZP 7-4NVSZP74NVSZP-74NVSZP 74